Pyoderma gangrenosum
MONDO:0018824Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.
20 clinical trials for this condition and its sub-types, 10 tagged with Pyoderma gangrenosum itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pyoderma gangrenosum
-
Classic pyoderma gangrenosum 3 trials
-
Bullous pyoderma gangrenosum 0 trials
-
Pustular pyoderma gangrenosum 0 trials
-
Vegetative pyoderma gangrenosum 0 trials
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase 4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a cream heal painful skin ulcers without pills?
Disease control Not yet recruitingThis phase 2 trial tests whether a topical cream containing ruxolitinib (OPZELURA) can completely heal painful ulcers in adults with pyoderma gangrenosum, a chronic inflammatory skin condition. About 12 participants will apply the cream twice daily for 24 weeks while continuing s…
Phase 2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can an existing skin drug heal rare, painful wounds?
Disease control Not yet recruitingThis study tests whether bimekizumab, a drug already approved for other skin conditions, can help heal wounds in people with pyoderma gangrenosum (PG), a rare and painful skin disorder. Adults with PG will receive injections of bimekizumab every few weeks for 24 weeks. The main g…
Phase 2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for painful skin ulcers: experimental drug enters human trials
Disease control Not yet recruitingThis phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the …
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New blood tests aim to unlock mysteries of rare inflammatory diseases
Knowledge-focused Not yet recruitingThis study aims to better understand rare autoinflammatory diseases by developing blood tests that measure inflammation markers. Researchers will analyze blood samples from 60 adults and children with these conditions. The goal is to identify specific inflammation pathways, which…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:44 UTC